Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 13;14(8):1963.
doi: 10.3390/cancers14081963.

The Landscape of lncRNAs in Multiple Myeloma: Implications in the "Hallmarks of Cancer", Clinical Perspectives and Therapeutic Opportunities

Ilaria Saltarella  1   2 , Benedetta Apollonio  1 , Aurelia Lamanuzzi  1 , Vanessa Desantis  1   2 , Maria Addolorata Mariggiò  3 , Jean-François Desaphy  2 , Angelo Vacca  1 , Maria Antonia Frassanito  3
Affiliations
Review

The Landscape of lncRNAs in Multiple Myeloma: Implications in the "Hallmarks of Cancer", Clinical Perspectives and Therapeutic Opportunities

Ilaria Saltarella et al. Cancers (Basel). .

Abstract

Long non-coding RNAs (lncRNAs) are transcripts longer than 200 nucleotides that are not translated into proteins. Nowadays, lncRNAs are gaining importance as key regulators of gene expression and, consequently, of several biological functions in physiological and pathological conditions, including cancer. Here, we point out the role of lncRNAs in the pathogenesis of multiple myeloma (MM). We focus on their ability to regulate the biological processes identified as "hallmarks of cancer" that enable malignant cell transformation, early tumor onset and progression. The aberrant expression of lncRNAs in MM suggests their potential use as clinical biomarkers for diagnosis, patient stratification, and clinical management. Moreover, they represent ideal candidates for therapeutic targeting.

Keywords: hallmarks of cancer; lncRNA; multiple myeloma; prognosis; therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
LncRNAs nomenclature. LncRNAs classification based on their orientation and location in the genomic loci.
Figure 2
Figure 2
Influence of lncRNA on multiple myeloma “Hallmarks of Cancer”.
See this image and copyright information in PMC

References

    1. Kumar S.K., Rajkumar V., Kyle R.A., van Duin M., Sonneveld P., Mateos M.V., Gay F., Anderson K.C. Multiple myeloma. Nat. Rev. Dis. Primers. 2017;3:17046. doi: 10.1038/nrdp.2017.46. - DOI - PubMed
    1. Di Marzo L., Desantis V., Solimando A.G., Ruggieri S., Annese T., Nico B., Fumarulo R., Vacca A., Frassanito M.A. Microenvironment drug resistance in multiple myeloma: Emerging new players. Oncotarget. 2016;7:60698–60711. doi: 10.18632/oncotarget.10849. - DOI - PMC - PubMed
    1. Hideshima T., Anderson K.C. Signaling Pathway Mediating Myeloma Cell Growth and Survival. Cancers. 2021;13:216. doi: 10.3390/cancers13020216. - DOI - PMC - PubMed
    1. Giuliani N., Colla S., Rizzoli V. Angiogenic switch in multiple myeloma. Hematology. 2004;9:377–381. doi: 10.1080/10245330400018524. - DOI - PubMed
    1. Neuse C.J., Lomas O.C., Schliemann C., Shen Y.J., Manier S., Bustoros M., Ghobrial I.M. Genome instability in multiple myeloma. Leukemia. 2020;34:2887–2897. doi: 10.1038/s41375-020-0921-y. - DOI - PubMed

LinkOut - more resources